In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
Pairing investigational peptide with Keytruda yields promising results for BioLineRx
Ziopharm provides update on Controlled IL-12 platform at Society for Neuro-Oncology meeting
Sitryx and Sygnature join hands to develop therapeutics in immuno-oncology and immuno-inflammation
Drug candidate minimizes cancer cell growth with minimal side effects
Preclinical efficacy data of Apogenix compound published in Frontiers in Oncology
Kadmon Holdings Inc. debuted preclinical data at the Society for Immunotherapy of Cancer’s Annual Meeting regarding KD033
The Society for Immunotherapy of Cancer’s 2018 meeting, held this November, saw Jounce Therapeutics Inc. share reverse translational and biomarker data from its ICONIC trial of JTX-2011
MorphoSys and I-Mab sign strategic agreement for novel immuno-oncology agent MOR210

Columbia Business School report examines how cancer drugs have impacted mortality for patients
by Dr. Eyal Talor, CEL-SCI
A look at what to expect from the second generation of cancer immunotherapies, after the progress--and pitfalls--of CAR-T cell therapies

by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.